Zobrazeno 1 - 10
of 292
pro vyhledávání: '"David M, Vail"'
Autor:
Valerie J. Poirier, Ethel S. Y. Koh, Johnson Darko, Andre Fleck, Christopher Pinard, David M. Vail
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 35, Iss 2, Pp 1062-1072 (2021)
Abstract Background Most dogs with sinonasal tumors (SNT) treated with radiation therapy (RT) died because of local disease progression. Hypothesis/Objectives Our hypothesis is that the majority of local failure and residual disease would occur withi
Externí odkaz:
https://doaj.org/article/0601efb5b1d04644b6fdda3847fa7828
Autor:
Jacob R. Cawley, Zachary M. Wright, Karri Meleo, Gerald S. Post, Craig A. Clifford, Kathryn R. Vickery, David M. Vail, Philip J. Bergman, Douglas H. Thamm
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 34, Iss 2, Pp 882-889 (2020)
Abstract Background Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L‐asparaginase (L‐ASP) has
Externí odkaz:
https://doaj.org/article/1ce026be3cc946338fa82f8615860027
Autor:
Michael Willmann, Vilma Yuzbasiyan-Gurkan, Laura Marconato, Mauro Dacasto, Emir Hadzijusufovic, Olivier Hermine, Irina Sadovnik, Susanne Gamperl, Mathias Schneeweiss-Gleixner, Karoline V. Gleixner, Thomas Böhm, Barbara Peter, Gregor Eisenwort, Richard Moriggl, Zhixiong Li, Mohamad Jawhar, Karl Sotlar, Erika Jensen-Jarolim, Veronika Sexl, Hans-Peter Horny, Stephen J. Galli, Michel Arock, David M. Vail, Matti Kiupel, Peter Valent
Publikováno v:
Frontiers in Veterinary Science, Vol 8 (2021)
Mast cell neoplasms are one of the most frequently diagnosed malignancies in dogs. The clinical picture, course, and prognosis vary substantially among patients, depending on the anatomic site, grade and stage of the disease. The most frequently invo
Externí odkaz:
https://doaj.org/article/4d0b2c0063b54593ba1b2814f43e664c
Autor:
Kara Magee, Ian R Marsh, Michelle M Turek, Joseph Grudzinski, Eduardo Aluicio-Sarduy, Jonathan W Engle, Ilene D Kurzman, Cindy L Zuleger, Elizabeth A Oseid, Christine Jaskowiak, Mark R Albertini, Karla Esbona, Bryan Bednarz, Paul M Sondel, Jamey P Weichert, Zachary S Morris, Reinier Hernandez, David M Vail
Publikováno v:
PLoS ONE, Vol 16, Iss 8, p e0255798 (2021)
RationaleMurine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present studies on the sa
Externí odkaz:
https://doaj.org/article/614577853cda400990756e8aa63b13c4
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The potential for companion (pet) species with spontaneously arising tumors to act as surrogates for preclinical development of advanced cancer imaging technologies has become more apparent in the last decade. The utility of the companion model speci
Externí odkaz:
https://doaj.org/article/79f3aa8d0eaf4f5bb4b3c6a23157a0d4
Autor:
Abbey R. Sadowski, Heather L. Gardner, Antonella Borgatti, Heather Wilson, David M. Vail, Joshua Lachowicz, Christina Manley, Avenelle Turner, Mary K. Klein, Angharad Waite, Alexandra Sahora, Cheryl A. London
Publikováno v:
BMC Veterinary Research, Vol 14, Iss 1, Pp 1-7 (2018)
Abstract Background Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable
Externí odkaz:
https://doaj.org/article/5970ac9c08524ac99e1ae4efc81b1bbf
Autor:
Amy K. LeBlanc, Christina N. Mazcko, Timothy M. Fan, David M. Vail, Brian K. Flesner, Jeffrey N. Bryan, Shan Li, Feng Wang, Scott Harris, Jesse D. Vargas, Jeevan P. Govindharajulu, Soumya Jaganathan, Francesca Tomaino, Apurva K. Srivastava, Tsui-Fen Chou, Gordon M. Stott, Joseph M. Covey, Barbara Mroczkowski, James H. Doroshow
Publikováno v:
Mol Cancer Ther
Pet dogs with naturally occurring cancers play an important role in studies of cancer biology and drug development. We assessed tolerability, efficacy, and pharmacokinetic/pharmacodynamic relationships with a first-in-class small molecule inhibitor o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c565201e4fd1dfd7a87c1b7df5687b36
https://doi.org/10.1158/1535-7163.mct-22-0167
https://doi.org/10.1158/1535-7163.mct-22-0167
Autor:
James H. Doroshow, Barbara Mroczkowski, Joseph M. Covey, Gordon M. Stott, Tsui-Fen Chou, Apurva K. Srivastava, Francesca Tomaino, Soumya Jaganathan, Jeevan P. Govindharajulu, Jesse D. Vargas, Scott Harris, Feng Wang, Shan Li, Jeffrey N. Bryan, Brian K. Flesner, David M. Vail, Timothy M. Fan, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Data from Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::306d21372321eea9e3620f450a0deeda
https://doi.org/10.1158/1535-7163.22523473.v1
https://doi.org/10.1158/1535-7163.22523473.v1
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 3 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf79f886bb73370f4df3bf2b203861b
https://doi.org/10.1158/1078-0432.22478240
https://doi.org/10.1158/1078-0432.22478240
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Fig. 1 depicts the chronology of clinical trial visits and associated procedures for dogs enrolled in this clinical trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e206106b269e032e0544bf85a04ba6
https://doi.org/10.1158/1078-0432.22478255
https://doi.org/10.1158/1078-0432.22478255